### In the Claims:

The current status of all claims is listed below and supercedes all previous lists of claims. Please cancel claims 39 to 45. Please also amend claims 1 to 3, 6, 10 to 17, 21 to 25, 32, 33, and 46 to 53 as follows.

### 1. (currently amended) A compound of formula (I):

wherein:

 $R^1$  is selected from H, optionally substituted  $C_{1-3}$ alkylaryl, optionally substituted  $C_1$ .

3alkylheterocycle, optionally substituted alkyl, optionally substituted  $C_{3-6}$ cycloalkyl,  $C_{2-4}$ 4alkylNR $^3$ R $^5$ , [[or]] and  $C_{1-4}$ alkylCOR $^d$ , wherein all such optional substitutions are made with 0, 1, 2 or 3 R $^c$ ;

 $R^a$  and  $R^b$  are, at each occurrence independently selected from H,  $C_{1^{-4}}$ alkyl [[or]] and  $C_{5^{-6}}$ cycloalkyl, or  $R^a$  and  $R^b$  and the N to which they are attached in combination form a 5 or 6-membered N-linked heterocycle having 2 nitrogen or, 1 nitrogen and 1 oxygen, ring atoms, wherein the non-linked nitrogen is substituted with  $R^c$ ;

 $R^c$  is, at each occurrence independently selected from H,  $C_{1^-3}$ alkyl, [[or]] and substituted phenyl with 0, 1, 2, or 3  $R^c$ ;

R<sup>d</sup> is, at each occurrence independently selected from C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy, [[or]] and

NR<sup>a</sup>R<sup>b</sup>:

 $R^e$  is, at each occurrence independently selected from OH, F, Cl, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>,  $C_{1\text{-o}}$ alkyl, or  $C_{1\text{-o}}$ alky

 $R^2$ ,  $R^3$ ,  $R^6$  and  $R^7$  are independently selected from H, optionally substituted 5- or 6-membered aromatic or heteroaromatic ring, said ring having 0, 1, 2 or 3, nitrogen, oxygen or sulfur atoms, but not more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom, optionally substituted  $C_{1-3}$ alkylaryl, optionally substituted  $C_{1-3}$ alkylatetrocycle, optionally substituted  $C_{1-6}$ alkyl, [[or]] and optionally substituted  $C_{3-6}$  cycloalkyl, wherein all such optional substitutions are made with 0, 1, 2, or 3  $R^{\circ}$  moieties, with the requirement that one or more of  $R^2$ ,  $R^3$ ,  $R^6$  and  $R^7$  are aromatic or heteroaromatic;

 $R^4$  is H, optionally substituted 5- or 6-membered aromatic or heteroaromatic ring, said ring having 0, 1, 2, or 3 0,1,2 or 3, nitrogen, oxygen or sulfur atoms, but not more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom,  $C_{1\text{-}6}$ alkyl,  $C_{2\text{-}6}$  cycloalkyl, or  $CR^9R^{10}R^{11}$ ;

 $R^9, R^{10}$  and  $R^{11}$  are, at each occurrence independently selected from H, F,  $C_{1\text{-4}}$ alkyl, OH, OCH<sub>3</sub>, SH, SCH<sub>3</sub>, and CH<sub>2</sub>SCH<sub>3</sub>:

R12 is phenyl substituted with 0, 1, 2 or 3 Re; and

R13 is C1-6alkyl or R12;

or a pharmaceutically acceptable salt thereof.

# (currently amended) A compound of claim 1, wherein:

 $R^1$  is selected from H, [[or]] and optionally substituted alkyl, wherein such optional substitution is made with 0, 1, or 2 substituents selected from  $C_1$ -6cycloalkyl,  $C_1$ -6cycloalkoxy, or phenyl;

 $R^2$ ,  $R^3$ ,  $R^6$  and  $R^7$  are independently selected from H, or optionally substituted 6-membered aromatic, wherein such optional substitution is made with 0, 1, 2, or 3  $R^e$  moieties, with the requirement that one or more of  $R^2$ ,  $R^3$ ,  $R^6$  and  $R^7$  are aromatic;

R4 is H. or C1-6alkvl:

R5 is -C1-6alkyl, or -C1-3alkylR12;

### DOCKET NO.: 133087.03501 (100911-1P US)

R12 is phenyl substituted with 0, 1, 2 or 3 Re;

 $R^e$  is, at each occurrence independently selected from OH, F, Cl, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>,  $C_{1\text{-o}alkyl}$ , [[or]] and  $C_{1\text{-o}alkyx}$ ;

or a pharmaceutically acceptable salt thereof.

(currently amended) A compound of claim 1, wherein:

 $R^1$  is selected from H, -C<sub>1-6</sub>alkyl, -(CH<sub>2</sub>)<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>-phenyl, -CH<sub>2</sub>C<sub>1-6</sub>cycloalkyl;  $R^2$ ,  $R^3$ ,  $R^6$  and  $R^7$  are independently selected from H, [[or]] and a substituted phenyl, wherein such substituent is selected from 1, 2, or 3 of the following F, Cl, Br, I or OCH<sub>3</sub>:

R4 is H. or C1-6alkvl;

 $R^5 \ \ is \ \ -C_{1^-6}alkyl, \ \underline{or} \ \ -C_{1^-3}alkylR^{12} \ \ wherein \ \ R^{12} \ \ is \ \ a \ substituted phenyl, \ wherein \ such ubstituent is selected from 1, 2 or 3 of the following F, Cl, Br, I [[or]] \ \underline{and} \ OCH_3;$ 

or a pharmaceutically acceptable salt thereof.

4. (previously presented) A compound of claim 1, wherein:

 $R^1$  is  $-C_{1-3}$ alkyl or  $-CH_2C_{1-4}$ cycloalkyl.

- (previously presented) A compound of claim 1, wherein:
   R<sup>1</sup> is methyl or -CH<sub>2</sub>cyclopropane.
- 6. (currently amended) A compound of claim 1, wherein:

 $R^e$  is, at each occurrence independently selected from F, Cl, CF<sub>3</sub>, C<sub>1-6</sub>alkyl, [[or]] and C<sub>1-6</sub>alkoxy.

(previously presented) A compound of claim 1, wherein:

 $R^2$  is an optionally substituted phenyl, wherein such optional substitution is made with 0, 1, 2, or 3  $R^s$  moieties.

8. (previously presented) A compound of claim 1, wherein:

R3, R6 and R7 are H.

- (previously presented) A compound of claim 1, wherein:
   R<sup>4</sup> is C<sub>1</sub>-6alkyl.
- 10. (currently amended) A compound of claim 1, wherein:  $R^5 \ \ is \ -C_{1^-6} alkyl \ \ or \ -C_{1^-3} alkyl R^{12} \ \ wherein \ \ R^{12} \ \ is \ \ a \ \ substituted \ phenyl, \ \ wherein \ \ such substitutent \ \ is \ selected \ \ from \ 1, 2 \ \ or \ 3 \ \ \ of the following F, Cl, Br, 1 [[or]] \ \ \underline{and} \ \ OCH_3.$
- (currently amended) A compound of claim 1 selected from:
   N²-[(3,5-difluorophenyl)acetyl]-N¹-[(3S,7S)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;
   N²-[(3,5-difluorophenyl)acetyl]-N¹-[(3S,7R)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1.

tetrahydro-1*H*-azenin-3-vll-L-alaninamide:

 $N^{1}$ -[(3S,7S)-1-(cyclopropylmethyl)-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]- $N^{2}$ -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

 $N^1$ -[(3S,7R)-1-(cyclopropylmethyl)-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]- $N^2$ -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

 $N^{1}-[(3S,7S)-1-\text{benzyl-}2-\text{oxo-}7-\text{phenyl-}2,3,4,7-\text{tetrahydro-}1H-\text{azepin-}3-\text{yl}]-N^{2}-[(3,5-1)-1]-N^{2}-[($ 

difluorophenyl)acetyl]-L-alaninamide;

 $N^{1}$ -[(3S,7R)-1-benzyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]- $N^{2}$ -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

 $\textit{N}^2\text{-}[(3,5\text{-difluorophenyl})\text{acetyl}]-\textit{N}^1\text{-}[(3S,7S)\text{-}1\text{-}(2\text{-methoxyethyl})\text{-}2\text{-}oxo\text{-}7\text{-phenyl-}]$ 

2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3,5,7*R*)-1-(2-methoxyethyl)-2-oxo-7-phenyl-

2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(2S)-2-hydroxy-4-methylpentanoyl]- $N^1$ -[(3S,7S)-1-(2-methoxyethyl)-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-leucinamide;

 $N^{1}$ -[(3R,7S)-1-cyclopentyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- $N^{2}$ -[(3,5-

difluorophenyl)acetyl]-L-alaninamide;

 $N^{1}$ -[(35,7s)-1-cyclopentyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]- $N^{2}$ -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

 $N^1$ -[(3R,7S)-1-isobutyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]- $N^2$ -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

 $N^{1}$ -[(3S,7S)-1-isobutyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]- $N^{2}$ -[(3,5-difluorophenyl)acetyl]-L-alaninamide:

 $N^{1}-[(3S,7S)-1-({\rm cyclopropylmethyl})-7-(4-{\rm fluorophenyl})-2-{\rm oxo}-2,3,4,7-{\rm tetrahydro}-1{\rm Hazepin-3-yl}]-N^{2}-[(3,5-{\rm difluorophenyl}){\rm acctyl}]-{\rm L-alaninamide};$ 

 $N^{l}-[(3R,7S)-1-(cyclopropylmethyl)-7-(4-fluorophenyl)-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-yl]- \\ N^{2}-[(3,5-difluorophenyl)acetyl]-L-alaninamide$ 

 $N^1$ -[(3S,7S)-1-(cyclopropylmethyl)-7-(4-methoxyphenyl)-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-yl]-  $N^2$ -[(3,5-difluorophenyl)acetyl]-L-alaninamide (11)

 $N^{1}$ -[(3R,7S)-1-(cyclopropylmethyl)-7-(4-methoxyphenyl)-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-yl]-  $N^{2}$ -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

 $N^{1}$ -[(3S,7S)-1-(cyclopropylmethyl)-7-(4-methoxyphenyl)-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-yl]- $N^{2}$ -[(2S)-2-hydroxy-4-methylpentanoyl]-L-leucinamide;

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,7S)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N<sup>2</sup>-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N<sup>1</sup>-[(3S,7S)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide:

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,7S)-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-vl]-L-alaninamide;

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,7S)-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S)-1-methyl-2-oxo-6-phenyl-2,3,4,7-tetrahydro-1H-azenin-3-yl-L-alaninamide:

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S)-2-oxo-6-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide:

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S)-1-methyl-2-oxo-6-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $\label{eq:local_problem} N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S)-1-methyl-2-oxo-6-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $\label{eq:N2-2-3,5-difluorophenyl} N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S)-2-oxo-6-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S)-2-oxo-6-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $\label{eq:N2-loss} N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(3S)-1-methyl-2-oxo-5-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S)-2-oxo-5-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $\label{eq:N2-2} N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^4-[(3S)-1-methyl-2-oxo-5-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $\label{eq:condition} N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^4-[(3S)-1-methyl-2-oxo-5-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S)-2-oxo-5-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S)-2-oxo-5-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,4S)-1-methyl-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-vl]-L-alaninamide;

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,4S)-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4S)-1-methyl-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N<sup>2</sup>-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N<sup>1</sup>-[(3S,4S)-1-methyl-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4S)-2-oxo-4-phenyl-2,3,4,7-

tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,4S)-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,4R)-1-methyl-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $\label{eq:N2-loss} N^2-[(3,5-\text{difluorophenyl})acetyl]-N^1-[(3S,4R)-2-\text{oxo-4-phenyl-2},3,4,7-\text{tetrahydro-1H-azepin-3-yl}]-L-\text{alaninamide};$ 

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4R)-1-methyl-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4R)-1-methyl-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4R)-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N<sup>2</sup>-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N<sup>1</sup>-[(3S,4R)-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azenin-3-vl]-L-alaninamide:

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^4$ -[(3S,4S,7S)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,4S,7S)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azenin-3-vl]-L-alaninamide:

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^4$ -[(3S,4S,7S)-1-methyl-2-oxo-4,7-diphenyl-2.3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide:

N<sup>2</sup>-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N<sup>1</sup>-[(3S,4S,7S)-1-methyl-2-oxo-4,7-diphenyl-2.3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide:

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^4$ -[(3S,4S,7S)-2-oxo-4,7-diphenyl-2.3,4.7-tetrahydro-1H-azenin-3-yl]-L-alaninamide:

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4S,7S)-2-oxo-4,7-diphenyl-2.3.4.7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N<sup>2</sup>-[(3,5-difluorophenyl)acetyl]-N<sup>1</sup>-[(3S,4R,7S)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahvdro-1H-azepin-3-yl]-L-alaninamide:

 $N^2-[(3.5-\text{difluorophenyl})acetyl]-N^1-[(3S,4R,7S)-2-\text{oxo-4},7-\text{diphenyl-2},3,4,7-\text{tetrahydro-1H-azepin-3-yl}]-L-\text{alaninamide};$ 

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4R,7S)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4R,7S)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4R,7S)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $\label{eq:N2-2} N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,4R,7S)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $\label{eq:N2-loss} N^2\text{--}[(3,5\text{-difluorophenyl})\text{acetyl}]\text{--}N^1\text{--}[(3S,4R,7R)\text{--1-methyl-2-oxo-4},7\text{--diphenyl-2},3,4,7\text{--tetrahydro-1H-azepin-3-yl}]\text{--L-alaninamide};$ 

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,4R,7R)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,4R,7R)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,4R,7R)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4R,7R)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4R,7R)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,7R)-1-methyl-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $\label{eq:N2-loss} N^2-[(3.5\text{-difluorophenyl})acetyl]-N^1-[(3S,7R)-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,7R)-1-methyl-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,7R)-1-methyl-2-oxo-5,7-

diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,7R)-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,7R)-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azenin-3-yl]-L-alaninamide:

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,7S)-1-methyl-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $\label{eq:N2-loss} N^2-[(3.5-\text{difluorophenyl})\text{acetyl}]-N^1-[(3S,7S)-2-\text{oxo-}5,7-\text{diphenyl-}2,3,4,7-\text{tetrahydro-}1\text{H-}\\ \text{azepin-}3-\text{vl}]-L-\text{alaninamide};$ 

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,7S)-1-methyl-2-oxo-5,7-diphenyl-2.3,4,7-tetrahydro-1H-azepin-3-vl]-L-alaninamide:

 $N^2-[(2R)-2-(3,5-\text{difluorophenyl})-2-\text{hydroxyacetyl}]-N^1-[(3S,7S)-1-\text{methyl}-2-\text{oxo}-5,7-\text{diphenyl}-2,3,4,7-\text{tetrahydro-1H-azepin-3-yl}-L-alaninamide;}$ 

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,7S)-2-oxo-5,7-diphenyl-2.3,4.7-tetrahydro-1H-azepin-3-yl]-L-alaninamide:

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,7S)-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,4R)-1-methyl-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^4$ -[(3S,4R)-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-vl]-L-alaninamide:

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4R)-1-methyl-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N<sup>2</sup>-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N<sup>1</sup>-[(3S,4R)-1-methyl-2-oxo-4,6-diphenyl-2.3,4.7-tetrahydro-1H-azepin-3-vl]-L-alaninamide:

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4R)-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4R)-2-oxo-4,6-diphenyl-2.3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide:

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,4S)-1-methyl-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^4$ -[(3S,4S)-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2-[(2S)-2-(3,5-\text{difluorophenyl})-2-\text{hydroxyacetyl}]-N^1-[(3S,4S)-1-\text{methyl}-2-\text{oxo}-4,6-\text{diphenyl}-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;}$ 

 $N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,4S)-1-methyl-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $\label{eq:N2-2} N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,4S)-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide; and$ 

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4S)-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide; or pharmaceutically acceptable salt thereof.

# 12. (currently amended) A compound of formula (II):

wherein:

 $R^1$  is selected from H, optionally substituted  $C_{1-3}$ alkylaryl, optionally substituted  $C_{1-3}$ alkylheterocycle, optionally substituted alkyl, optionally substituted  $C_{3-6}$ cycloalkyl,  $C_{2-6}$ 

 $_4$ alkylNR $^4$ R $^6$ , [[or]] and  $C_{1^-4}$ alkylCOR $^d$ , wherein all such optional substitutions are made with 0, 1, 2 or 3 R $^c$ ;

 $R^a$  and  $R^b$  are, at each occurrence independently selected from H,  $C_{1^{-4}}$ alkyl [[or]] and  $C_{5^{-6}}$ cycloalkyl, or  $R^a$  and  $R^b$  and the N to which they are attached in combination form a 5 or 6-membered N-linked heterocycle having 2 nitrogen or, 1 nitrogen and 1 oxygen, ring atoms, wherein the non-linked nitrogen is substituted with  $R^c$ ;

 $R^c$  is, at each occurrence independently selected from H,  $C_{1-2}$ alkyl, [[or]] and substituted phenyl with 0, 1, 2, or 3  $R^c$ ;

 $R^d$  is, at each occurrence independently selected from  $C_{1\text{--3}}$ alkyl,  $C_{1\text{--3}}$ alkoxy, [[or]] and  $NR^aR^b$ ;

 $R^e$  is, at each occurrence independently selected from OH, F, Cl, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>,  $C_{1\text{-calkyl}}$ , [[orl] and  $C_{1\text{-calkyl}}$ , ([orl] and  $C_{1\text{-calkyl}}$ )

 $R^2$ ,  $R^3$ ,  $R^6$  and  $R^7$  are independently selected from H, optionally substituted 5- or 6-membered aromatic or heteroaromatic ring, said ring having  $\theta_{1,1,2}$  or 3 0, 1, 2, or 3, nitrogen, oxygen or sulfur atoms, but not more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom, optionally substituted  $C_{1-3}$ alkylaryl, optionally substituted  $C_{1-3}$ alkylheterocycle, optionally substituted  $C_{1-6}$ alkyl, [[or]] and optionally substituted  $C_{3-6}$  cycloalkyl, wherein all such optional substitutions are made with 0, 1, 2, or 3  $R^6$  moieties, with the requirement that one or more of  $R^2$ ,  $R^3$ ,  $R^6$  and  $R^7$  are aromatic or heteroaromatic:

 $R^4$  is H, optionally substituted 5- or 6-membered aromatic or heteroaromatic ring, said ring having 0,1,2 or 3, nitrogen, oxygen or sulfur atoms, but not more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom,  $C_{1-6}$ alkyl,  $C_{3-6}$  cycloalkyl, or  $CR^9R^{10}R^{11}$ ;

R<sup>5</sup> is C<sub>1</sub>-3alkylR<sup>12</sup> or CH(OH)R<sup>13</sup>;

 $R^9, R^{10}$  and  $R^{11}$  are, at each occurrence independently selected from H, F,  $C_{1^{-4}}$ alkyl, OH, OCH<sub>3</sub>, SH, SCH<sub>3</sub>, and CH<sub>2</sub>SCH<sub>3</sub>:

 $R^{12}$  is phenyl substituted with 0, 1, 2 or 3  $R^e$ ;

R13 is C1-6alkyl or R12;

or a pharmaceutically acceptable salt thereof.

13. (currently amended) A compound of claim 12, wherein:

 $R^1$  is selected from H, [[or]] <u>and</u> optionally substituted alkyl wherein such optional substitution is made with 0, 1, or 2 substituents selected from  $C_{1^-6}$ cycloalkyl,  $C_{1^-6}$ cycloalkoxy, [[or]] and phenyl;

R<sup>2</sup>, R<sup>3</sup>, R<sup>6</sup> and R<sup>7</sup> are independently selected from H, [[or]] and optionally substituted 6-membered aromatic, wherein such optional substitution is made with 0, 1, 2, or 3 R<sup>8</sup> moieties, with the requirement that one or more of R<sup>2</sup>, R<sup>3</sup>, R<sup>6</sup> and R<sup>7</sup> are aromatic:

R4 is H, or C1-6alkyl;

R5 is C1-3alkvlR12 or C1-6alkvl;

R<sup>12</sup> is phenyl substituted with 0, 1, 2 or 3 R<sup>e</sup>;

R<sup>o</sup> is, at each occurrence independently selected from OH, F, Cl, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, C<sub>1-calkyl</sub>, or C<sub>1-calkoxy</sub>;

or a pharmaceutically acceptable salt thereof.

14. (currently amended) A compound of claim 12, wherein:

 $R^1 \ is \ selected \ from \ H, \ -C_{1}\text{-}6alkyl, \ -(CH_2)_2OCH_3, \ -CH_2\text{-}phenyl, \ \underline{and} \ -CH_2C_{1}\text{-}6cycloalkyl;$ 

 $R^2$ ,  $R^3$ ,  $R^6$  and  $R^7$  are independently selected from H, [[or]] and a substituted phenyl, wherein such substitutent is selected from 1, 2, or 3 of the following F, Cl, Br, I [[or]] and OCH<sub>3</sub>:

R<sup>4</sup> is H, or C<sub>1</sub>-6alkyl;

R<sup>5</sup> is -C<sub>1</sub>-6alkyl, or -C<sub>1</sub>-3alkylR<sup>12</sup> wherein R<sup>12</sup> is a substituted phenyl, wherein such substituent is selected from 1, 2 or 3 of the following F, Cl. Br. I Horll and OCH<sub>3</sub>.

or a pharmaceutically acceptable salt thereof.

- (currently amended) A compound of claim 12, wherein:
   R<sup>1</sup> is selected from -C<sub>1</sub>-alkyl, Horll and -CH<sub>2</sub>C<sub>1</sub>-acycloalkyl.
- (currently amended) A compound of claim 12, wherein:
   R<sup>1</sup> is selected from methyl [[or]] and -CH<sub>2</sub>cyclopropane.

- (currently amended) A compound of claim 12, wherein:
   Re is at each occurrence independently selected from F, Cl, CF<sub>3</sub>, C<sub>1-6</sub>alkyl, [[or]] and C<sub>1</sub>.
   6alkoxy.
- 18. (original) A compound of claim 12, wherein:
  R<sup>2</sup> is an optionally substituted phenyl, wherein such optional substitution is made with
  0.1, 2, or 3 R° moieties.
- (original) A compound of claim 12, wherein:
   R<sup>3</sup>. R<sup>6</sup> and R<sup>7</sup> are H.
- (original) A compound of claim 12, wherein:
   R<sup>4</sup> is C<sub>1-6</sub>alkyl.
- 21. (currently amended) A compound of claim 12, wherein:  $R^5 \ \ is \ \, -C_{1-5} alky | R^{12} \ \ wherein \ \, R^{12} \ \ is \ \, a \ \, substituted \ \, phenyl, \ \, wherein \ \, such substitutent is selected from 1, 2 or 3 of the following F, Cl, Br, I [for] and OCHs.$
- 22. (currently amended) A compound of claim 12 selected from:  $N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(3S,7S)-1-methyl-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$
- $N^2-[(3.5-difluorophenyl)acetyl]-N^1-[(3S,7S)-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide; \\$
- N<sup>2</sup>-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N<sup>1</sup>-[(3S,7S)-1-methyl-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- $N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,7S)-1-methyl-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide; \\$ 
  - $N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,7S)-2-oxo-7-phenyl-2,3,6,7-n]-2-(3S,7S)-2-oxo-7-phenyl-2,3,6,7-n]-2-(3S,7S)-2-oxo-7-phenyl-2,3,6,7-n]-2-(3S,7S)-2-oxo-7-phenyl-2,3,6,7-n]-2-(3S,7S)-2-oxo-7-phenyl-2,3,6,7-n]-2-(3S,7S)-2-oxo-7-phenyl-2,3,6,7-n]-2-(3S,7S)-2-oxo-7-phenyl-2,3,6,7-n]-2-(3S,7S)-2-oxo-7-phenyl-2,3,6,7-n]-2-(3S,7S)-2-oxo-7-phenyl-2,3,6,7-n]-2-(3S,7S)-2-oxo-7-phenyl-2,3,6,7-n]-2-(3S,7S)-2-oxo-7-phenyl-2,3,6,7-n]-2-(3S,7S)-2-oxo-7-phenyl-2,3,6,7-n]-2-(3S,7S)-2-oxo-7-phenyl-2,3,6,7-n]-2-(3S,7S)-2-($

tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2-[(2R)-2-(3.5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,7S)-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $N^2-[(3.5-difluorophenyl)acetyl]-N^1-[(3S,7R)-1-methyl-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide; \\$ 

 $N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(3S,7R)-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-vl]-L-alaninamide; \\$ 

 $N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,7R)-1-methyl-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

N<sup>2</sup>-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N<sup>1</sup>-[(3S,7R)-1-methyl-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,7R)-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,7R)-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(3S,6R)-1-methyl-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide; \\$ 

 $N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(3S,6R)-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide; \\$ 

N<sup>2</sup>-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N<sup>1</sup>-[(3S,6R)-1-methyl-2-oxo-6phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide:

 $N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,6R)-1-methyl-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,6R)-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azenin-3-vl]-L-alaninamide:

 $N^2-[(2R)-2-(3.5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,6R)-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-vll-L-alaninamide;$ 

 $N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(3S,6S)-1-methyl-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide; \\$ 

 $N^2-[(3.5-difluorophenyl)acetyl]-N^1-[(3S,6S)-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,6S)-1-methyl-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide; \\$ 

 $N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,6S)-1-methyl-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide; \\$ 

 $N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,6S)-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,6S)-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $\label{eq:N2-loss} N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(3S)-1-methyl-2-oxo-5-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(3S)-2-oxo-5-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide; \\$ 

 $N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S)-1-methyl-2-oxo-5-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S)-1-methyl-2-oxo-5-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S)-2-oxo-5-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S)-2-oxo-5-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(3S)-1-methyl-2-oxo-4-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $N^2-[(3.5-difluorophenyl)acetyl]-N^1-[(3S)-2-oxo-4-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide; \\$ 

 $N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S)-1-methyl-2-oxo-4-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;$ 

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S)-1-methyl-2-oxo-4-phenyl-

2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

 $N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S)-2-oxo-4-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide; and \\$ 

N<sup>2</sup>-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N<sup>1</sup>-[(3S)-2-oxo-4-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide; or pharmaceutically acceptable salt thereof.

## 23. (currently amended) A compound of formula (III):

wherein:

 $R^1$  is selected from H, optionally substituted  $C_{1:3}$ alkylaryl, optionally substituted  $C_{1:3}$ alkylheterocycle, optionally substituted alkyl, optionally substituted  $C_{2:6}$ cycloalkyl,  $C_{2:4}$ alkylNR\*R\*, [[or]] and  $C_{1:4}$ alkylCOR\*, wherein all such optional substitutions are made with 0, 1, 2 or 3 R\*;

 $R^a$  and  $R^b$  are, at each occurrence independently selected from H.  $C_{1^{-4}}$ alkyl [[or]] and  $C_{5^{-6}}$ cycloalkyl, or  $R^a$  and  $R^b$  and the N to which they are attached in combination form a 5 or 6-membered N-linked heterocycle having 2 nitrogen or, 1 nitrogen and 1 oxygen, ring atoms, wherein the non-linked nitrogen is substituted with  $R^c$ ;

 $R^c$  is, at each occurrence independently selected from H,  $C_{1^{-3}}alkyl,\ \hbox{\hbox{\small [[or]]}}\ \underline{and}$ 

substituted phenyl with 0, 1, 2, or 3 Re;

 $R^d$  is, at each occurrence independently selected from  $C_{1^{-3}}$ alkyl,  $C_{1^{-3}}$ alkoxy, [[or]] and  $NR^aR^b$ :

 $R^{\circ}$  is, at each occurrence independently selected from OH, F, Cl, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, C<sub>1-6</sub>alkyl, [[ort]] and C<sub>1-6</sub>alkoxy;

 $R^2$ ,  $R^3$  and  $R^7$  are independently selected from H, optionally substituted  $C_{1:3}$ alkylaryl, optionally substituted  $C_{1:3}$ alkylaryletorocycle, optionally substituted 5- or 6-membered aromatic or heteroaromatic ring, said ring having 0,1,2 or 3, nitrogen, oxygen or sulfur atoms, but not more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom, optionally substituted  $C_{1:6}$ alkyl, [[or]] and optionally substituted  $C_{3:6}$  cycloalkyl, wherein all such optional substitutions are made with 0, 1, 2, or 3  $R^6$  moieties, with the requirement that one or more of  $R^2$ ,  $R^3$  and  $R^7$  are aromatic or heteroaromatic:

 $R^6$  is independently selected from H, optionally substituted  $C_{1-3}$ alkylaryl, optionally substituted  $C_{1-3}$ alkylheterocycle, optionally substituted  $C_{1-6}$ alkyl, [[or]] and optionally substituted  $C_{3-6}$  cycloalkyl, wherein all such optional substitutions are made with 0, 1, 2, or 3  $R^\circ$  moieties;

 $R^4$  is H, optionally substituted 5- or 6-membered aromatic or heteroaromatic ring, said ring having 0,1,2 or 3, nitrogen, oxygen or sulfur atoms, but not more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom,  $C_{1^-6}$ alkyl,  $C_{3^-6}$  cycloalkyl, or  $CR^9R^{10}R^{11}$ ;

R<sup>5</sup> is -C<sub>1</sub>-6alkyl, -C<sub>1</sub>-3alkylR<sup>12</sup> or CH(OH)R<sup>13</sup>;

 $R^9$ ,  $R^{10}$  and  $R^{11}$  are, at each occurrence independently selected from H, F,  $C_{1\text{-4}}$ alkyl, OH, OCH<sub>3</sub>, SH, SCH<sub>3</sub>, and CH<sub>2</sub>SCH<sub>3</sub>;

 $R^{12}$  is phenyl substituted with 0, 1, 2 or 3  $R^e$ ;

R13 is C1-6alkyl or R12;

or a pharmaceutically acceptable salt thereof.

### (currently amended) A compound of claim 23, wherein:

 $R^1$  is selected from H, [[or]] and optionally substituted alkyl, wherein such optional substitution is made with 0, 1, or 2 substituents selected from  $C_{176}$ cycloalkyl,  $C_{176}$ cycloalkoxy,

[[or]] and phenyl;

 $R^2$ ,  $R^3$ ,  $R^6$  and  $R^7$  are independently selected from H, [[or]] and optionally substituted 6-membered aromatic, wherein such optional substitution is made with 0, 1, 2, or 3  $R^6$  moieties, with the requirement that one or more of  $R^2$ ,  $R^3$ ,  $R^6$  and  $R^7$  are aromatic:

R4 is H, or C1-6alkvl;

R5 is -C1-6alkyl or-C1-3alkylR12;

R<sup>12</sup> is phenyl substituted with 0, 1, 2 or 3 R°;

R° is, at each occurrence independently selected from OH, F, Cl, Br, I, CN, NO<sub>2</sub>, CF<sub>3</sub>, C<sub>1-calkyl</sub>, [[ort] and C<sub>1-calky</sub>;

or a pharmaceutically acceptable salt thereof.

25. (currently amended) A compound of claim 23, wherein:

 $R^1$  is selected from H, -C<sub>1</sub>-6alkyl, -(CH<sub>2</sub>)<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>-phenyl, [[or]] and -CH<sub>2</sub>C<sub>1</sub>-6cycloalkyl;

 $R^2$ ,  $R^3$ ,  $R^6$  and  $R^7$  are independently selected from H, [[or]] and a substituted phenyl, wherein such substituent is selected from 1, 2, or 3 of the following F, Cl, Br, I [[or]] and OCH<sub>3</sub>:

R4 is H, or C1-6alkyl;

 $R^5$  is  $-C_{1^-6}$ alkyl or  $-C_{1^-3}$ alkyl $R^{12}$  wherein  $R^{12}$  is a substituted phenyl, wherein such substituent is selected from 1, 2 or 3 of the following F, Cl, Br, I  $\lceil |\sigma| \rceil$  and OCH<sub>3</sub>:

or a pharmaceutically acceptable salt thereof.

26. (previously presented) A compound of claim 23, wherein:

 $R^1$  is -C<sub>1</sub>-6alkyl or -CH<sub>2</sub>C<sub>1</sub>-4cycloalkyl.

27. (original) A compound of claim 23, wherein:

R1 is methyl or -CH2cyclopropane.

28. (original) A compound of claim 23, wherein:

Re is, at each occurrence independently selected from F, Cl, CF<sub>3</sub>, C<sub>1-6</sub>alkyl, or C<sub>1</sub>.

### DOCKET NO.: 133087.03501 (100911-1P US)

6alkoxy.

- 29. (original) A compound of claim 23, wherein:
- $R^2$  is an optionally substituted phenyl, wherein such optional substitution is made with 0, 1, 2, or 3  $R^\circ$  moieties.
- 30. (original) A compound of claim 23, wherein: R<sup>3</sup>. R<sup>6</sup> and R<sup>7</sup> are H.
- (original) A compound of claim 23, wherein:
   R<sup>4</sup> is C<sub>1</sub>-6alkyl.
- 32. (currently amended) A compound of claim 23, wherein:

 $R^5 \ \ is \ -C_{1^-6} alkyl \ \ or \ -C_{1^-3} alkyl R^{12} \ \ wherein \ \ R^{12} \ \ is \ \ a \ substituted \ phenyl, \ \ wherein \ \ such substitutent is selected from 1, 2 or 3 of the following F, Cl, Br, I [[or]] \ \underline{and} \ OCH_3.$ 

- 33. (currently amended) A compound of claim 23 selected from:
- $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,7S)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide:
- $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,7R)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide:
- $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3R,7S)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide:
- $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3R,7R)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide (3 $\Rightarrow$ ):
- $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,7R)-2-oxo-7-phenylazepan-3-yl]-L-alaninamide:
- $\label{eq:N2-loss} N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,7R)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;$

 $\label{eq:N2-loss} N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,7R)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;$ 

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,7R)-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,7R)-2-oxo-7-phenylazepan-3-yl]-L-alaninamide:

 $\label{eq:N2-loss} N^2\text{-}[(3,5\text{-difluorophenyl})\text{acetyl}]\text{-}N^1\text{-}[(3S,7S)\text{-}2\text{-}\text{oxo-7-phenylazepan-3-yl}]\text{-}L\text{-}alaninamide;}$ 

 $N^2-[\{2S\}-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[\{3S,7S\}-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;$ 

 $\label{eq:N2-local} \textit{N}^2\text{--}[(2R)\text{-}2\text{-}(3,5\text{--}difluorophenyl)\text{-}}2\text{--}hydroxyacetyl]\text{--}\textit{N}^1\text{--}[(3S,7S)\text{--}1\text{--}methyl\text{-}}2\text{--}oxo\text{-}7\text{--}phenylazepan-3-yl]\text{--}L-alaninamide;}$ 

 $N^2\text{-}[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,7S)-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;$ 

 $N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^4-[(3S,7S)-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;$ 

 $\label{eq:N2-lambda} \textit{N}^2\text{-}[(3,5\text{-difluorophenyl})acetyl]-\textit{N}^1\text{-}[(3S,6R)-1\text{-methyl}-2\text{-oxo-6-phenylazepan-3-yl}]-L-alaninamide;}$ 

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,6R)-2-oxo-6-phenylazepan-3-yl]-L-alaninamide:

 $N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,6R)-1-methyl-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;$ 

 $\label{eq:N2-2} N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,6R)-1-methyl-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;$ 

 $\label{eq:N2-2} N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,6R)-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;$ 

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,6R)-1-methyl-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,6S)-1-methyl-2-oxo-6-phenylazepan-3-yl]-L-

alaninamide;

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,6S)-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;

 $\label{eq:N2-loss} N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,6S)-1-methyl-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;$ 

 $\label{eq:N2-loss} N^2\text{-}[(2R)\text{-}2\text{-}(3,5\text{-}difluorophenyl)\text{-}2-hydroxyacetyl}]-N^1\text{-}[(3S,6S)\text{-}1\text{-}methyl\text{-}2-oxo-6-phenylazepan-3-yl}\text{-}L\text{-}alaninamide;}$ 

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,6S)-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,6S)-2-oxo-6-phenylazepan-3-yl]-L-alaninamide:

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,4R)-1-methyl-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,4R)-2-oxo-4-phenylazepan-3-yl]-L-alaninamide:

 $\label{eq:N2-loss} N^2\text{-}[(2S)\text{-}2\text{-}(3,5\text{-}difluorophenyl)\text{-}2\text{-}hydroxyacetyl]}-N^1\text{-}[(3S,4R)\text{-}1\text{-}methyl\text{-}2\text{-}oxo\text{-}4\text{-}phenylazepan-}3\text{-}yl]\text{-}L\text{-}alaninamide;}$ 

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^4$ -[(3S,4R)-1-methyl-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4R)-2-oxo-4-phenylazepan-3-yl]-L-alaninamide:

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4R)-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,4S)-1-methyl-2-oxo-4-phenylazepan-3-yl]-L-alaninamide:

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,4S)-2-oxo-4-phenylazepan-3-yl]-L-alaninamide:

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4S)-1-methyl-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;

 $\label{eq:N2-loss} N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,4S)-1-methyl-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;$ 

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4S)-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4S)-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^4$ -[(3S,4R,7S)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

 $\label{eq:N2-loss} \textit{N}^2\text{-}[(3,5\text{-}difluorophenyl)acetyl]-\textit{N}^1\text{-}[(3S,4R,7S)\text{-}2\text{-}oxo\text{-}4,7\text{-}diphenylazepan-3-yl]-L-alaninamide;}$ 

 $N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,4R,7S)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;$ 

 $\label{eq:N2-local} N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,4R,7S)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;$ 

 $\label{eq:N2-loss} N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,4R,7S)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;$ 

 $\label{eq:N2-loss} N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,4R,7S)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;$ 

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^4$ -[(3S,4S,7S)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^4$ -[(3S,4S,7S)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4S,7S)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4S,7S)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

 $N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,4S,7S)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;$ 

 $N^2$ -[(2R)-2-(3.5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4S,7S)-2-oxo-4.7-

diphenylazepan-3-yl]-L-alaninamide;

 $\label{eq:N2-landau} \textit{N}^2-[(3,5\text{-difluorophenyl})acetyl]-\textit{N}^1-[(3S,4R,7R)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;}$ 

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,4R,7R)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide:

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4R,7R)-1-methyl-2-oxo-4,7-diphenylazepan-3-v|]-L-alaninamide:

 $N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,4R,7R)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;$ 

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4R,7R)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

 $N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,4R,7R)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;$ 

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^4$ -[(3S,4R,6S)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,4R,6S)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide:

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4R,6S)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4R,6S)-1-methyl-2-oxo-4,6-diphenylazepan-3-vl]-L-alaninamide:

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4R,6S)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4R,6S)-2-oxo-4,6-diphenylazenan-3-yl]-L-alaninamide:

 $\label{eq:N2-landau} \textit{N}^2-[(3.5\text{-difluorophenyl})acetyl]-\textit{N}^1-[(3S,4S,6S)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;}$ 

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,4S,6S)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide:

 $N^2-[(2S)-2-(3,5-\text{difluorophenyl})-2-\text{hydroxyacetyl}]-N^1-[(3S,4S,6S)-1-\text{methyl}-2-\text{oxo-}4,6-\text{diphenylazepan-}3-yl]-L-alaninamide;}$ 

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4S,6S)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,4S,6S)-2-oxo-4,6-diphenylazepan-3-vl]-L-alaninamide:

 $N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,4S,6S)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;$ 

 $\label{eq:N2-loss} \textit{N}^2\text{-}[(3,5\text{-difluorophenyl})acetyl]-\textit{N}^1\text{-}[(3S,4R,6R)-1\text{-methyl}-2\text{-}oxo-4,6\text{-diphenyl}azepan-3-yl]-L-alaninamide;}$ 

 $\label{eq:N2-loss} N^2\text{-}[(3,5\text{-}difluorophenyl)acetyl]-N^1\text{-}[(3S,4R,6R)\text{-}2\text{-}oxo\text{-}4,6\text{-}diphenylazepan-3-yl]-L-alaninamide;}$ 

 $\label{eq:N2-2} N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,4R,6R)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;$ 

 $\label{eq:N2-2} N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,4R,6R)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;$ 

 $\label{eq:N2-[2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,4R,6R)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;$ 

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^4$ -[(3S,4R,6R)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

 $\label{eq:N2-lambda} \textit{N}^2-[(3.5\text{-difluorophenyl})\text{acetyl}]-\textit{N}^1-[(3S,5R,7S)-1-\text{methyl}-2-\text{oxo-5},7-\text{diphenylazepan-3-yl}-L-\text{alaninamide};$ 

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,5R,7S)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

 $\label{eq:N2-loss} N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,5R,7S)-1-methyl-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;$ 

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,5R,7S)-1-methyl-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

N<sup>2</sup>-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N<sup>1</sup>-[(3S,5R,7S)-2-oxo-5,7-

diphenylazepan-3-yl]-L-alaninamide;

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,5R,7S)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

 $\label{eq:N2-lambda} \textit{N}^2-[(3,5-\text{difluorophenyl})\text{acetyl}]-\textit{N}^1-[(3S,5S,7S)-1-\text{methyl}-2-\text{oxo}-5,7-\text{diphenylazepan-3-yl}-L-\text{alaninamide};$ 

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,5S,7S)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide:

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,5S,7S)-1-methyl-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,5S,7S)-1-methyl-2-oxo-5,7-diphenylazepan-3-vl]-L-alaninamide:

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,5S,7S)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^4$ -[(3S,5S,7S)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide:

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,5R,7R)-1-methyl-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,5R,7R)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide:

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,5R,7R)-1-methyl-2-oxo-5,7-diphenylazepan-3-v|l-L-alaninamide:

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,5R,7R)-1-methyl-2-oxo-5,7-diphenylazenan-3-vl]-L-alaninamide:

 $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,5R,7R)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide:

 $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,5R,7R)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

 $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,5S)-1-methyl-2-oxo-5-phenylazepan-3-yl]-L-alaninamide:

- $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,5S)-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;
- $\label{eq:N2-loss} N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,5S)-1-methyl-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;$
- $\label{eq:N2-loss} N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,5S)-1-methyl-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;$
- $N^2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(3S,5S)-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;$
- $N^2$ -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^1$ -[(3S,5S)-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;
- $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,5R)-1-methyl-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;
- $N^2$ -[(3,5-difluorophenyl)acetyl]- $N^1$ -[(3S,5R)-2-oxo-5-phenylazepan-3-yl]-L-alaninamide:
- $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^4$ -[(3S,5R)-1-methyl-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;
- $N^2-[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^4-[(3S,5R)-1-methyl-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;$
- $N^2$ -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- $N^i$ -[(3S,5R)-2-oxo-5-phenylazepan-3-yl]-L-alaninamide; and
- $N^2\text{-}[(2R)\text{-}2\text{-}(3,5\text{-}difluorophenyl})\text{-}2\text{-}hydroxyacetyl}]\text{-}N^4\text{-}[(3S,5R)\text{-}2\text{-}oxo\text{-}5\text{-}phenylazepan-}3\text{-}yl]\text{-}L\text{-}alaninamide;}$
- or pharmaceutically acceptable salt thereof.
- 34.-45. (canceled).
- 46. (Currently Amended) A method for inhibiting γ-secretase activity comprising administering to a host a therapeutically effective amount of mixing a compound of claim 1 with γ-secretase under conditions such that γ-secretase activity is inhibited.

### DOCKET NO.: 133087.03501 (100911-1P US)

- 47. (currently amended) A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient.
- 48. (currently amended) A process for preparing a compound of formula 1f

comprising reacting tert-butyl[(3S,7S)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-vllcarbamate with triflouroacetic acid.

49. (currently amended) A process for preparing a compound of formula 1

comprising reacting a compound of formula 1f

and N-[(3,5-difluorophenyl)acetyl]-L-alanine with HOBt-hydrate, and N-methyl morpholine.

50. (currently amended) A process for preparing a compound of formula 2e

comprising reacting benzyl [(3S,7S)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]carbamate with H<sub>2</sub> and Pearlman's Catalyst in <u>ETOH ethanol</u>.

51. (currently amended) A process for preparing a compound of formula 2

comprising reacting (3S,7S)-3-amino-1-methyl-7-phenylazepan-2-one and N-[(3,5-difluorophenyl)acetyl]-L-alanine with HOBt-hydrate, EDAC.HCl and N-methyl morpholine.

52. (currently amended) A process for preparing (3R,7S)-3-amino-1-(cyclopropylmethyl)-

### DOCKET NO.: 133087.03501 (100911-1P US)

7-(4-methoxyphenyl)-1,3,4,7-tetrahydro-2H-azepin-2-one comprising reacting a compound of formula 11d

114

with H2NNH2 in MeOH methanol.

53. (currently amended) A process for preparing a compound of formula 11A

comprising reacting (3R,7S)-3-amino-1-(cyclopropylmethyl)-7-(4-methoxyphenyl)-1,3,4,7-tetrahydro-2H-azepin-2-one and N-[(3,5-difluorophenyl)acetyl]-L-alanine with with HOBt-hydrate, EDAC.HCl and N-methyl morpholine.